Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

SLE subjects:

• Female subjects 18 years or older who meets > 3 of 11 modified Am. Coll. ofRheumatology (ACR) (1997) Revised Criteria for SLE and mild/moderate diseaseactivity defined as an SLE Disease Activity Index 2000(SLEDAI 2K) between zero andless than or equal to 14 at screening;

• If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stablefor at least 4 weeks prior to screening;

• If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine,dose must have been stable for the 12 weeks prior to screening. The max. alloweddoses - hydroxychloroquine 400 mg/day, chloroquine phosphate 500 mg/day andquinacrine 100 mg/day;

• If on immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil,cyclosporine, tacrolimus); dose must have been stable for the 12 weeks prior toscreening

• Subjects of childbearing potential must agree to practice effective birth controlfor the duration of the study;

• Stated willingness to comply with all study procedures and availability for theduration of the study;

• Agreement to adhere to Lifestyle Considerations throughout study duration;

• Ability of subject to understand and the willingness to sign a written informedconsent document.

• If on vitamin B3 or tryptophan supplementation at screening, willing to stop it atleast 6 weeks before the baseline visit.

Control subjects:

• Female subjects 18 years or older

• No history of autoimmune or inflammatory disease

• If on vitamin B3 or tryptophan supplementation at screening, willing to stop it atleast 6 weeks before the blood draw visit.

EXCLUSION CRITERIA:

SLE Subjects:

• Active renal or central nervous system disease or major renal or hepaticdysfunction;

• Treatment with rituximab, belimumab or any other biologic agent within the 6 monthsprior to screening

• Treatment with cyclophosphamide or IVIG within the 6 months prior to screening andor increase in glucocorticoid dose within 4 weeks of screening;

• Pregnancy or lactation (nursing)

• Treatment with another investigational drug or other intervention within 6 months ofscreening

Control Subjects:

• Inability to sign consent

• Pregnancy or nursing

Pregnant women are excluded from participation on this study. Self-reported pregnancy status may be accepted from female control participants of child-bearing potential for a blood draw which is considered a minimal risk procedure.